Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 27Thoracic 13Sarcoma 7Lymphoid 4Tumor-Agnostic 2Gynecologic 2Other solid neoplasm 1Gastrointestinal 1

Conditions

Hodgkin Disease 4Recurrence 2

Interventions

Cyclophosphamide 342Rituximab 304Vincristine 157Doxorubicin 154venetoclax 153fludarabine 153Specimen Handling 152Prednisone 150Biopsy 122Magnetic Resonance Spectroscopy 117obinutuzumab 116Lenalidomide 109Dexamethasone 104Cytarabine 97ibrutinib 95Etoposide 92fludarabine phosphate 87Methotrexate 84acalabrutinib 78Bendamustine Hydrochloride 72zanubrutinib 71blinatumomab 63pembrolizumab 62CT-P10 60Gemcitabine 51Nivolumab 45glofitamab 44Calcium Dobesilate 44Mercaptopurine 43prednylidene 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Vinorelbine × Lymphoid × 1 year × Clear all
NCT07021989 2026-06-04

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

University of California, San Francisco

Phase 2 Not yet recruiting
38 enrolled
Lymphoid

Hodgkin Disease

NCT06377566 2026-04-23

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
71 enrolled
Lymphoid

Hodgkin Disease

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
257 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT05300282 2026-01-28

FIL_A-BEGEV

Fondazione Italiana Linfomi - ETS

Phase 1/2 Recruiting
122 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡